ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) is expected to be posting its Q1 2025 quarterly earnings results before the market opens on Thursday, May 8th. Analysts expect the company to announce earnings of ($0.09) per share and revenue of $4.90 million for the quarter.
ProQR Therapeutics Stock Down 10.8 %
Shares of NASDAQ:PRQR traded down $0.20 during trading on Tuesday, hitting $1.61. The stock had a trading volume of 217,237 shares, compared to its average volume of 610,824. ProQR Therapeutics has a 12-month low of $1.07 and a 12-month high of $4.62. The stock has a market capitalization of $168.87 million, a price-to-earnings ratio of -5.05 and a beta of 0.35. The stock has a 50-day simple moving average of $1.55 and a two-hundred day simple moving average of $2.45.
Wall Street Analyst Weigh In
Several analysts have commented on the stock. Evercore ISI started coverage on shares of ProQR Therapeutics in a research note on Tuesday, April 29th. They set an "outperform" rating and a $5.00 price objective for the company. Oppenheimer began coverage on shares of ProQR Therapeutics in a report on Friday, January 10th. They issued an "outperform" rating and a $15.00 price target on the stock. Citigroup upgraded ProQR Therapeutics from a "neutral" rating to a "buy" rating and set a $4.00 price objective for the company in a research note on Monday, March 10th. Cantor Fitzgerald started coverage on ProQR Therapeutics in a research note on Tuesday, April 29th. They issued an "overweight" rating and a $8.00 target price on the stock. Finally, HC Wainwright lifted their price target on ProQR Therapeutics from $10.00 to $12.00 and gave the company a "buy" rating in a research report on Friday, March 14th. One research analyst has rated the stock with a sell rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $8.75.
View Our Latest Stock Report on ProQR Therapeutics
About ProQR Therapeutics
(
Get Free Report)
ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).
Featured Stories
Before you consider ProQR Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ProQR Therapeutics wasn't on the list.
While ProQR Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
